Psychedelic-assisted psychotherapy (PAP) constitutes a novel treatment paradigm in mental health care practice that is currently being evaluated for its clinical efficacy and safety. Insight into the attitudes of clinicians toward PAP remains crucial for its successful integration into mental health care. This cross-sectional survey explores the attitudes of Dutch mental health care...
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...